BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 506 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,704,623 | +3.2% | 98,496 | +23.7% | 0.01% | 0.0% |
| Q2 2023 | $6,498,564 | -73.4% | 79,610 | -75.8% | 0.01% | -73.1% |
| Q1 2023 | $24,421,419 | +1337.9% | 329,174 | +1506.3% | 0.03% | +1200.0% |
| Q4 2022 | $1,698,460 | -82.2% | 20,493 | -39.0% | 0.00% | -81.8% |
| Q3 2022 | $9,548,000 | -21.3% | 33,621 | -4.0% | 0.01% | -21.4% |
| Q2 2022 | $12,134,000 | +83.2% | 35,007 | +128.8% | 0.01% | +133.3% |
| Q1 2022 | $6,624,000 | +18.2% | 15,298 | +41.3% | 0.01% | +20.0% |
| Q4 2021 | $5,602,000 | -54.1% | 10,828 | -57.0% | 0.01% | -54.5% |
| Q3 2021 | $12,212,000 | -44.0% | 25,200 | -47.9% | 0.01% | -42.1% |
| Q2 2021 | $21,788,000 | +141.4% | 48,389 | +104.8% | 0.02% | +111.1% |
| Q1 2021 | $9,024,000 | +6.9% | 23,627 | -11.1% | 0.01% | +28.6% |
| Q4 2020 | $8,438,000 | +10.5% | 26,571 | -13.8% | 0.01% | -22.2% |
| Q3 2020 | $7,638,000 | +41.9% | 30,832 | +51.2% | 0.01% | +50.0% |
| Q2 2020 | $5,384,000 | -53.9% | 20,388 | -66.9% | 0.01% | -66.7% |
| Q1 2020 | $11,689,000 | -30.3% | 61,642 | -19.4% | 0.02% | -5.3% |
| Q4 2019 | $16,780,000 | +14.6% | 76,444 | +2.2% | 0.02% | +5.6% |
| Q3 2019 | $14,642,000 | +31.1% | 74,829 | +39.7% | 0.02% | +28.6% |
| Q2 2019 | $11,165,000 | +27.8% | 53,551 | +21.7% | 0.01% | +27.3% |
| Q1 2019 | $8,734,000 | -22.2% | 43,988 | -43.3% | 0.01% | -26.7% |
| Q4 2018 | $11,223,000 | +254.4% | 77,547 | +399.7% | 0.02% | +275.0% |
| Q3 2018 | $3,167,000 | -36.8% | 15,518 | -54.2% | 0.00% | -42.9% |
| Q2 2018 | $5,014,000 | +8.6% | 33,888 | +10.8% | 0.01% | +16.7% |
| Q1 2018 | $4,619,000 | -16.0% | 30,581 | -27.9% | 0.01% | -25.0% |
| Q4 2017 | $5,496,000 | +48.2% | 42,421 | +38.3% | 0.01% | +33.3% |
| Q3 2017 | $3,709,000 | +17.5% | 30,684 | +14.2% | 0.01% | +20.0% |
| Q2 2017 | $3,157,000 | +57.0% | 26,866 | +35.8% | 0.01% | +25.0% |
| Q1 2017 | $2,011,000 | -38.5% | 19,786 | -37.8% | 0.00% | -33.3% |
| Q4 2016 | $3,271,000 | -15.1% | 31,806 | -9.6% | 0.01% | -14.3% |
| Q3 2016 | $3,854,000 | -57.4% | 35,192 | -56.2% | 0.01% | -58.8% |
| Q2 2016 | $9,057,000 | +85.2% | 80,314 | +55.2% | 0.02% | +88.9% |
| Q1 2016 | $4,891,000 | +574.6% | 51,746 | +542.0% | 0.01% | +800.0% |
| Q4 2015 | $725,000 | -18.4% | 8,060 | -16.2% | 0.00% | 0.0% |
| Q3 2015 | $889,000 | +17.6% | 9,619 | +25.4% | 0.00% | 0.0% |
| Q2 2015 | $756,000 | +39.7% | 7,670 | +42.3% | 0.00% | 0.0% |
| Q1 2015 | $541,000 | – | 5,391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |